TOKYO (dpa-AFX) - Vical Inc. (VICL) announced the U.S. FDA has granted the company Fast Track designation for its investigational antifungal product candidate, VL-2397, for the treatment of invasive aspergillosis.
Larry Smith, Vical's Vice President of Vaccine Research, said: 'The Fast Track designation for VL-2397, in addition to the qualified infectious disease product and the orphan drug designations already granted by the FDA, can facilitate expedited development of VL-2397.'
VL-2397 was initially developed by Astellas Pharma Inc. In March 2015, Astellas granted Vical an exclusive worldwide license to develop and commercialize VL-2397.
Copyright RTT News/dpa-AFX
© 2016 AFX News
